From 1988 until earlier this year, Hobbs was president and CEO of AngioDynamics, Inc. Throughout his tenure at AngioDynamics, Hobbs led the company’s efforts in marketing, strategic planning, product development, and general management. In 2004, AngioDynamics was spun off from E-Z-EM, Inc., where Hobbs served as senior vice-president since 1988.

Before his involvement with these companies, Hobbs was the director of marketing and product development at NAMIC, Founder, president and CEO of Hobbs Medical, Inc., and a product development engineer at Cook Incorporated. He received a Bachelor of Science in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts in 1980. In addition, Hobbs was elected to and currently serves on the board of directors of the Society of Interventional Radiology Foundation and as vice chairman of the Medical Device Manufacturers Association.

Commenting on his new position at Delcath Systems, Hobbs stated, “I am delighted to be leading Delcath during this exciting time in our development. Richard has done an exceptional job leading the Company over the past two-plus years and I look forward to building on recent achievements. The promise of our drug delivery platform and its unique position in the interventional oncology space offers the opportunity to address a large and growing unmet medical need. I look forward to completing our Phase III clinical trials and submitting for FDA approval in a timely manner. At the same time, we will focus on expanding our presence and relationships within the medical community and look forward to delivering this exciting treatment modality to oncology patients worldwide.”

“Eamonn is a proven leader with extensive experience in all aspects of medical device commercialization and the entire Board feels that he is the best person to lead our Company through the next phase of our development,” added Dr. Harold Koplewicz, chairman of Delcath Systems’ board.

Commenting on this transition, Taney stated, “The Delcath management team and our Board of Directors are very proud of the tremendous progress our Company has made over the past two and a half years. As we approach completion of our pivotal Phase III trial, we are increasingly shifting our focus towards the commercialization of our technology. I look forward to working with Eamonn during this transition and to my continued involvement as a committed member of our Board of Directors.”

Delcath Systems is a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver.